EGFR、ALK基因突变阴性晚期重症肺腺癌长生存个案报道并文献复习

Long-Term Survival of Advanced Severe Lung Adenocarcinoma with Negative EGFR and ALK Gene Mutation: A Case Report and Literature Review

肺癌目前仍然是全球死亡人数最多的恶性肿瘤,总体的5年生存率不到20%。非小细胞肺癌(non-small cell lung cancer, NSCLC)大约占到肺癌的85%~90%,大部分患者在病情进展到晚期时才确诊,而且非所有肺癌患者有靶向和免疫治疗的机会。本案例报道了一例晚期EGFR、ALK基因突变阴性重症肺腺癌患者先后通过化疗、免疫治疗、靶向治疗及放疗多线治疗获得至少3.4年的总生存期。

Lung cancer is the leading cause of cancer death currently in the world, of which the 5-year survival rate is about 20%. Non-small cell lung cancer (NSCLC) accounts for about 85%~90% of lung carcinoma, and most patients are diagnosed at advanced stages, while not all patients have opportunities for targeting therapy and immunotherapy. This case report describes a patient who had advanced severe lung adenocarcinoma with negative EGFR and ALK mutation, and he has achieved an overall survival of at least 3.4 years with multiple-line therapies including chemotherapy, immunotherapy, targeted therapy and radiotherapy.